Evidence map›Paper›PMID 28122974›Full record

ArticleJournal of virology2017

Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent Manner.

Thomas Musich, Liuzhe Li, Lily Liu, Susan Zolla-Pazner, Marjorie Robert-Guroff, Miroslaw K Gorny

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. The Hitchhiker Guide to CD4Frontiers in immunology · 2021
    Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Thomas MusichVaccine Branch, NCI, NIH, Bethesda, Maryland, USA.
Liuzhe LiDepartment of Pathology, New York University School of Medicine, New York, New York, USA.
Lily LiuDepartment of Pathology, New York University School of Medicine, New York, New York, USA.
Susan Zolla-PaznerDivision of Infectious Diseases, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID http://orcid.org/0000-0002-0750-2666
Marjorie Robert-GuroffVaccine Branch, NCI, NIH, Bethesda, Maryland, USA.
Miroslaw K GornyDepartment of Pathology, New York University School of Medicine, New York, New York, USA mirek.gorny@nyumc.org.
New York University · USNational Institutes of Health · USIcahn School of Medicine at Mount Sinai · US

Funding

Development of a Vaccine for HIVAIDS: Humoral ImmunityZIABC011058 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROBERT-GUROFF, MARJORIE · 2009 to 2020
$23.3M
Vaccines to Induce Functional Antibodies Targeting the V2 Loop P01AI100151 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WANG, SHIXIA · 2012 to 2017
$15.4M
Protective role of V2 antibodies induced at mucosal tissues in macaquesR01AI112546 · NIAID · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI GORNY, MIROSLAW K · 2015 to 2019
$3.1M
NIAID NIH HHS P01 AI100151NIAID NIH HHS R01 AI112546
6 · The paper itself

Abstract

In light of the weak or absent neutralizing activity mediated by anti-V2 monoclonal antibodies (MAbs), we tested whether they can mediate Ab-dependent cellular phagocytosis (ADCP), which is an important element of anti-HIV-1 immunity. We tested six anti-V2 MAbs and compared them with 21 MAbs specific for V3, the CD4-binding site (CD4bs), and gp41 derived from chronically HIV-1-infected individuals and produced by hybridoma cells. ADCP activity was measured by flow cytometry using uptake by THP-1 monocytic cells of fluorescent beads coated with gp120, gp41, BG505 SOSIP.664, or BG505 DS-SOSIP.664 complexed with MAbs. The measurement of ADCP activity by the area under the curve showed significantly higher activity of anti-gp41 MAbs than of the members of the three other groups of MAbs tested using beads coated with monomeric gp41 or gp120; anti-V2 MAbs were dominant compared to anti-V3 and anti-CD4bs MAbs against clade C gp120

Indexed as

PhagocytosisAntibodies, MonoclonalBinding SitesCell LineFlow CytometryHIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41HumansImmunoglobulin GMonocytesAntibodies, Monoclonalgp120 protein, Human immunodeficiency virus 1gp41 protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120HIV Envelope Protein gp41Immunoglobulin Ganti-CD4bs MAbsanti-gp41 MAbsanti-HIV-1 antibodiesanti-V2 MAbsanti-V3 MAbsHIV-1human monoclonal antibodiesIgG3phagocytosis

Identifiers

PMID28122974
PMCPMC5375680
OpenAlexW2884222216

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.